A. Leone

发表

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep‐2 cancer cells

F. Bruzzese, E. Di Gennaro, A. Budillon, 2011, Proteomics.

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT

M. Caraglia, F. Bruzzese, E. Di Gennaro, 2011, Journal of cellular physiology.

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance

F. Caponigro, F. Bruzzese, E. Di Gennaro, 2020, Frontiers in Cell and Developmental Biology.

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways

R. Franco, M. Caraglia, A. Luciano, 2013, Cell Death and Disease.

Microenvironment and Immunology Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF 15

F. Bruzzese, A. Budillon, L. Egevad, 2014 .

Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood

G. Avvisati, C. Almici, S. Miscia, 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

The Crosstalk between Cancer Stem Cells and Microenvironment Is Critical for Solid Tumor Progression: The Significant Contribution of Extracellular Vesicles

A. Budillon, A. Leone, C. Ciardiello, 2018, Stem cells international.

HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation

L. Altucci, F. Bruzzese, E. Di Gennaro, 2022, Journal of experimental & clinical cancer research : CR.

Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models

S. Costantini, F. Bruzzese, A. Budillon, 2022, Journal of translational medicine.

A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges

G. Avvisati, G. Musolino, C. Almici, 2018, Scientific Reports.

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study

A. Zaniboni, G. Ritorto, M. Di Maio, 2021, ESMO open.

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol

F. Izzo, P. Delrio, G. Botti, 2020, Therapeutic advances in medical oncology.

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

M. Caraglia, S. Costantini, F. Bruzzese, 2013, Cell Death and Disease.

Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake

F. Bruzzese, E. Di Gennaro, A. Budillon, 2019, Molecular Cancer Therapeutics.

Vorinostat potentiates cisplatin-5-fluorouracil combination by inhibiting 1 chemotherapy-induced EGFR nuclear translocation and increasing cisplatin 2 uptake.

F. Bruzzese, A. Budillon, E. Gennaro, 2019 .

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53

P. Delrio, F. Bruzzese, E. Di Gennaro, 2017, Journal of Experimental & Clinical Cancer Research.

Targeting Autophagy in Breast Cancer

A. Budillon, M. Capozzi, F. Di Rella, 2020, International journal of molecular sciences.

Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15.

T. Sjöblom, F. Bruzzese, A. Budillon, 2014, Cancer research.

Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches

S. Costantini, A. Budillon, A. Leone, 2017, Oxidative medicine and cellular longevity.

Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer

F. Izzo, P. Delrio, G. Botti, 2021, JAMA network open.

Large extracellular vesicles: Size matters in tumor progression.

A. Budillon, A. Leone, C. Ciardiello, 2019, Cytokine & growth factor reviews.

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation

Valentina R Minciacchi, D. Di Vizio, V. Gigantino, 2019, Journal of Experimental & Clinical Cancer Research.

New perspective for an old antidiabetic drug: metformin as anticancer agent.

Antonio Avallone, F. Bruzzese, E. Di Gennaro, 2014, Cancer treatment and research.

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition

R. Mancini, G. Ciliberto, S. Costantini, 2020, Journal of experimental & clinical cancer research : CR.

Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.

Gennaro Ciliberto, Rita Mancini, R. Mancini, 2015, Free radical biology & medicine.

Management of non-small cell lung cancer in the era of personalized medicine.

F. Fiore, A. Budillon, P. Muto, 2016, The international journal of biochemistry & cell biology.

Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles

F. Ungaro, A. Budillon, F. Tatangelo, 2016, Oncotarget.

Restoring p53 Function: Novel Anticancer Approaches for an Old Foe

F. Bruzzese, A. Budillon, E. Gennaro, 2012 .

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression

R. Franco, F. Bruzzese, E. Di Gennaro, 2015, Oncotarget.

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression

R. Mancini, G. Ciliberto, F. Bruzzese, 2016, Oncotarget.

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed

P. Delrio, F. Bruzzese, E. Di Gennaro, 2009, Cancer biology & therapy.

Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial

Antonella Petrillo, Vincenza Granata, Gerardo Botti, 2015, Oncotarget.

Multidisciplinary approach to rectal cancer: are we ready for selective treatment strategies?

P. Delrio, A. Avallone, A. Budillon, 2013, Anti-cancer agents in medicinal chemistry.

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

Antonella Petrillo, Vincenza Granata, Gerardo Botti, 2016, BMC Cancer.

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

M. Caraglia, S. Costantini, F. Bruzzese, 2013, Cell Death and Disease.

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53

P. Delrio, F. Bruzzese, E. Di Gennaro, 2017, Journal of experimental & clinical cancer research : CR.

TARGETING VEGF-A TO TREAT CANCER AND OTHER DISORDERS oral

M. Anadkat, F. Bruzzese, L. Egevad, 2009 .

IDENTIFICATION OF NOVEL SECRETED TUMOR STROMA-DERIVED STIMULATORS OF PROSTATE CANCER GROWTH

Å. Borg, F. Bruzzese, L. Egevad, 2009 .

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

M. Caraglia, F. Bruzzese, E. Di Gennaro, 2014, Cell Death and Disease.

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition

R. Mancini, G. Ciliberto, S. Costantini, 2020, Journal of experimental & clinical cancer research : CR.

Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood

G. Avvisati, C. Almici, S. Miscia, 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

SO-26 Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study

G. Troncone, A. Avallone, A. Budillon, 2023, Annals of Oncology.

Abstract LB-219: Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers.

P. Delrio, A. Avallone, A. Budillon, 2012 .